🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology · Phase III

Autoimmune & immunology programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
368

Quick answer

Autoimmune & immunology Phase III programs: NovaPharmaNews indexes 368 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 4 of 8

  1. JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  2. JNJ-80202135, Placebo subcutaneous without Nipocalimab

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets

    Alfasigma S.p.A.

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  4. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP

    Alfasigma S.p.A.

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  5. Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets, GLPG0634

    Alfasigma S.p.A.

    Polyarticular-course juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  6. KHK4827

    KYOWA KIRIN AUSTRALIA PTY LTD

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  7. KYV-101

    Kyverna Therapeutics

    Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome

    phase 3 small molecule active

    1 trial

  8. LY2127399

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  9. LY2127399

    Eli Lilly and Company

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  10. Lansoprazole and naproxen and aspirin

    Takeda

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  11. Leflunomide Mylan 10 mg, filmomhulde tabletten, PLACEBO

    Disc Medicine

    polymyalgia rheumatica

    phase 3 small molecule active

    1 trial

  12. METHOTREXATE, LENALIDOMIDE, LENALIDOMIDE

    Pari Pharma GmbH

    Cutaneous lupus erythematosus

    phase 3 small molecule active

    1 trial

  13. METHYLPREDNISOLONE , PREDNISONE , Gazyvaro 1,000 mg concentrate for solution for infusion., Obinutuzumab placebo, Myfenax 500 mg film-coated tablets, DIPHENHYDRAMINE , PARACETAMOL

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 3 small molecule active

    1 trial

  14. MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte

    Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimmune hemolytic anemia

    phase 3 small molecule active

    1 trial

  15. MK-6194, Placebo for MK-6194

    Merck Sharp and Dohme

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  16. MMX Mesalamine/Mesalazine (Low Dose)

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  17. MT-5547

    Tanabe Pharma

    Osteoarthritis, Knee / Osteoarthritis, Hip

    phase 3 small molecule completed

    1 trial

  18. MYCOPHENOLATE MOFETIL, PREDNISOLONE , MYCOPHENOLATE MOFETIL, AZATHIOPRINE, Gazyvaro 1,000 mg concentrate for solution for infusion., AZATHIOPRINE

    Pari Pharma GmbH

    lupus nephritis

    phase 3 small molecule active

    1 trial

  19. MYCOPHENOLIC ACID, -, MYCOPHENOLATE MOFETIL, VAY736, TENOFOVIR ALAFENAMIDE , ENTECAVIR , TENOFOVIR DISOPROXIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  20. MYCOPHENOLIC ACID, TENOFOVIR ALAFENAMIDE , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe , Placebo to VAY736 300 mg/2 mL Solution for injection in pre-filled syringe, VAY736, ENTECAVIR , -, TENOFOVIR DISOPROXIL , VAY736, MYCOPHENOLATE MOFETIL

    Novartis Pharmaceuticals

    Lupus nephritis

    phase 3 small molecule active

    1 trial

  21. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite BioPharma

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  22. Matching Placebo for TAK-279 Dose A, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, ZASOCITINIB

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  23. Matching Placebo for TAK-279 Dose B, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose A

    Takeda

    Active Psoriatic Arthritis Stratified by Prior Biologic Use

    phase 3 small molecule active

    1 trial

  24. Matching Placebo for TAK-279, ZASOCITINIB

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  25. Matching Placebo for Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  26. Medi-546

    AstraZeneca

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  27. Mirikizumab

    Eli Lilly and Company

    Ulcerative Colitis

    phase 3 small molecule active

    2 trials

  28. Mirikizumab SC

    Eli Lilly and Company

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  29. Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  30. Mirikizumab, Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  31. Mirikizumab, Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  32. Mirikizumab, Tirzepatide, to match Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  33. MomeGalen 1 mg/g cutaneous emulsion, Placebo to 0.1% mometasone furoate cutaneous emulsion (active ingredient-free vehicle of mometasone cutaneous emulsion), ECURAL Fettcreme, 1 mg/g Creme

    Lacuna Pharma Pty Ltd

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  34. NEORAL® Soft Gelatin Capsules 100mg, Methotrexate 2.5 mg Tablets, Zilbrysq 16.6 mg solution for injection in pre-filled syringe, Prednisolone 5mg Tablets, Azathioprine Tablets 50mg Oprisine, Privigen 100 mg/ml solution for infusion, Soliris 300 mg concentrate for solution for infusion, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 50mg, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 10mg, Methotrexate 2.5 mg Tablets, Methotrexate 2.5 mg Tablets, NEORAL® Soft Gelatin Capsules 25mg, K

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  35. NI-501; emapalumab, NI-501; emapalumab

    Swedish Orphan Biovitrum Pty Ltd

    Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).

    phase 3 small molecule active

    1 trial

  36. NNC0487-0111 B 10142, NNC0487-0111 B 10141, Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  37. ORENCIA 250 mg powder for concentrate for solution for infusion, METHOTREXATE/PFIZER, ORENCIA 250 mg powder for concentrate for solution for infusion, ORENCIA 250 mg powder for concentrate for solution for infusion, DRL_AB

    Dr Reddy''s Laboratories (Australia) Pty Ltd

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  38. Obexelimab

    Zenas BioPharma

    Warm Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    1 trial

  39. Olokizumab

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  40. Olokizumab 64 mg SC q4w

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  41. Olokizumab 64mg q4w

    International Peace Maternity and Child Health Hospital

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  42. Omvoh 300 mg concentrate for solution for infusion, Omvoh 100 mg solution for injection in pre-filled syringe

    Eli Lilly Co.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  43. Ontamalimab

    Takeda

    Ulcerative Colitis

    phase 3 small molecule terminated

    3 trials

  44. Ontamalimab

    Shire

    Crohn's Disease

    phase 3 small molecule terminated

    1 trial

  45. Ontamalimab

    Takeda

    Crohn's Disease

    phase 3 mab terminated

    3 trials

  46. Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Orforglipron, Placebo to match LY

    Eli Lilly Co.

    Osteoarthritis

    phase 3 small molecule active

    1 trial

  47. Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  48. Otezla 10mg, 20mg, 30 mg film-coated tablets, Otezla 10mg, 20mg, 30 mg film-coated tablets, Apremilast placebo (same excipient as over-encapsulated Otezla), Otezla 10mg, 20mg, 30 mg film-coated tablets, ZASOCITINIB, Otezla 30 mg film-coated tablets, TAK-279 placebo (same excipient as TAK-279)

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology Phase III programs exist?

368 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.